Great Valley Advisor Group’s Plus Therapeutics PSTV Stock Holding History

Great Valley Advisor Group’s Portfolio PSTV Stock Details PSTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-90	Closed	-$9.74K	–	734
2023 Q1	$9.74K	Hold	90	–	–	﹤0.01%	693
2022 Q4	$10.7K	Hold	90	–	–	﹤0.01%	685
2022 Q3	$15K	Hold	90	–	–	﹤0.01%	663
2022 Q2	$18K	Buy	+90	New	+$22.5K	﹤0.01%	662

Other funds holding PSTV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Great Valley Advisor Group's PSTV Position: Q2 2023 in Review

Great Valley Advisor Group sold out of Plus Therapeutics (PSTV) in Q2 2023, closing a stake of 90 shares — an estimated $9.74K sold.

Great Valley Advisor Group first reported a position in PSTV in Q2 2022 and held it in 4 quarters. The position peaked at $18K in Q2 2022. 6 funds tracked by Wall St. Rank hold PSTV as of Q2 2023.

Great Valley Advisor Group reported no remaining Plus Therapeutics position as of Q2 2023 after selling out during the quarter.
Great Valley Advisor Group sold 90 Plus Therapeutics shares in Q2 2023, an estimated $9.74K.
Great Valley Advisor Group first reported a position in Plus Therapeutics in Q2 2022 and held it in 4 quarters.
Great Valley Advisor Group's Plus Therapeutics position peaked at $18K in Q2 2022.
6 funds tracked by Wall St. Rank held Plus Therapeutics as of Q2 2023.

Based on Great Valley Advisor Group's 13F filing for Q2 2023, filed 10 Aug 2023.